1. BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis
- Author
-
Chien Jui Cheng, Li Yuan Yu-Lee, Sue Hwa Lin, Yu Chen Lee, Jing Fang Lu, Mehmet Asim Bilen, Sankar N. Maity, Gary E. Gallick, and Robert L. Satcher
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Bone Neoplasms ,Bone Morphogenetic Protein 4 ,Mice, SCID ,Adenocarcinoma ,urologic and male genital diseases ,Bone morphogenetic protein ,Article ,Mice ,Prostate cancer ,Subcutaneous Tissue ,Osteogenesis ,Prostate ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Bone morphogenetic protein receptor ,skin and connective tissue diseases ,Autocrine signalling ,Bone Morphogenetic Protein Receptors, Type I ,Osteoblasts ,business.industry ,Ossification, Heterotopic ,Prostatic Neoplasms ,Osteoblast ,medicine.disease ,Xenograft Model Antitumor Assays ,Recombinant Proteins ,Neoplasm Proteins ,Autocrine Communication ,Pyrimidines ,medicine.anatomical_structure ,Cytokine ,Oncology ,Bone morphogenetic protein 4 ,Culture Media, Conditioned ,Cancer research ,Cytokines ,Intercellular Signaling Peptides and Proteins ,Pyrazoles ,business - Abstract
Induction of new bone formation is frequently seen in the bone lesions from prostate cancer. However, whether osteogenesis is necessary for prostate tumor growth in bone is unknown. Recently, 2 xenografts, MDA-PCa-118b and MDA-PCa-133, were generated from prostate cancer bone metastases. When implanted subcutaneously in severe combined immunodeficient (SCID) mice, MDA-PCa-118b induced strong ectopic bone formation while MDA-PCa-133 did not. To identify the factors that are involved in bone formation, we compared the expression of secreted factors (secretome) from MDA-PCa-118b and MDA-PCa-133 by cytokine array. We found that the osteogenic MDA-PCa-118b xenograft expressed higher levels of bone morphogenetic protein BMP4 and several cytokines including interleukin-8, growth-related protein (GRO), and CCL2. We showed that BMP4 secreted from MDA-PCa-118b contributed to about a third of the osteogenic differentiation seen in MDA-PCa-118b tumors. The conditioned media from MDA-PCa-118b induced a higher level of osteoblast differentiation, which was significantly reduced by treatment with BMP4 neutralizing antibody or the small molecule BMP receptor 1 inhibitor LDN-193189. BMP4 did not elicit an autocrine effect on MDA-PCa-118b, which expressed low to undetectable levels of BMP receptors. Treatment of SCID mice bearing MDA-PCa-118b tumors with LDN-193189 significantly reduced tumor growth. Thus, these studies support a role of BMP4-mediated osteogenesis in the progression of prostate cancer in bone. Cancer Res; 71(15); 5194–203. ©2011 AACR.
- Published
- 2011